Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER(+) HER2(-) locally-advanced or metastatic breast cancer.

Liang J, Ong C, Heslop K, Guan J, Kameswaran V, Daniel B, Shi M, Liang Y, Giltnane JM, Aimi J, Chang CW, Gates MR, Eng-Wong J, Perez-Moreno P, Jhaveri KL, Turner NC, Lim E, Metcalfe C, Moore HM

Open source

DOI
10.1038/s41467-026-71233-1
Published
2026 Apr 1
Container
Nature communications
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1038/s41467-026-71233-1,
  title = {Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER(+) HER2(-) locally-advanced or metastatic breast cancer.},
  author = {Liang J and Ong C and Heslop K and Guan J and Kameswaran V and Daniel B and Shi M and Liang Y and Giltnane JM and Aimi J and Chang CW and Gates MR and Eng-Wong J and Perez-Moreno P and Jhaveri KL and Turner NC and Lim E and Metcalfe C and Moore HM},
  year = {2026},
  journal = {Nature communications},
  doi = {10.1038/s41467-026-71233-1},
  url = {https://doi.org/10.1038/s41467-026-71233-1}
}

RIS

TY  - JOUR
TI  - Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER(+) HER2(-) locally-advanced or metastatic breast cancer.
AU  - Liang J
AU  - Ong C
AU  - Heslop K
AU  - Guan J
AU  - Kameswaran V
AU  - Daniel B
AU  - Shi M
AU  - Liang Y
AU  - Giltnane JM
AU  - Aimi J
AU  - Chang CW
AU  - Gates MR
AU  - Eng-Wong J
AU  - Perez-Moreno P
AU  - Jhaveri KL
AU  - Turner NC
AU  - Lim E
AU  - Metcalfe C
AU  - Moore HM
PY  - 2026
JO  - Nature communications
DO  - 10.1038/s41467-026-71233-1
UR  - https://doi.org/10.1038/s41467-026-71233-1
ER  - 

APA

J, L., C, O., K, H., J, G., V, K., B, D., M, S., Y, L., JM, G., J, A., CW, C., MR, G., J, E., P, P., KL, J., NC, T., E, L., C, M., & HM, M. (2026). Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER(+) HER2(-) locally-advanced or metastatic breast cancer.. Nature communications. https://doi.org/10.1038/s41467-026-71233-1

Source records